Glaxo Agrees To $65M Settlement In Antitrust Suit Over Paxil Patent Gaming: Report

Law360, New York (February 3, 2005, 12:00 AM EST) -- In a deal that closely resembles similar settlements for arthritis drug Relafen and prescription antibiotic Augmentin, GlaxoSmithKline has reportedly agreed to pay $65 million to settle a class action antitrust suit brought by consumers who accused the U.K. drug maker of filing "sham" patent lawsuits to delay generic competition for antidepressant Paxil.

In the proposed settlement, which is awaiting final approval by U.S. District Judge John R. Padova, Glaxo admitted no liability and maintains its position that its litigation efforts were not designed to cause any...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.